Overview

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Clopidogrel
Ticagrelor
Ticlopidine